Rapid access to clinical data and results to accelerate drug development
Data Sciences
You need data rapidly to make crucial decisions during a study. Faster data means we can provide our customers with earlier interim data and interim PK reports for on-study dosing and formulation decisions.
We understand on-study changes to early phase study designs and dosing are frequent and so our study strategy for study database design and reporting is built around flexibility and rapid implementation. We use eSource data collection procedures in our clinical units and a joint eSource/eCRF database. Data are available in the study database within hours of collection, ready for remote sponsor access.
Our data science experts support studies conducted at our US and UK clinics. With global SOPs, templates and standards, we also adapt them for use with sponsor templates/standards. Our services are fully integrated and we assign a single Project Manager for all drug product, clinical and data sciences activities. Data Science at Quotient comprises six specialist departments and over 80 staff:
Data Management and Database Programming
- Study eSource/eCRF database set-up and maintenance
- Study database build using Anju’s TrialOne system, a single system for both eSource collection in clinic and eCRF for data management. As a result, TrialOne use and Quotient processes reduce data transcription and timelines.
- Data Management Plan, data cleaning, coding, query issue and database lock
Statistics and Statistical Programming
- Protocol input, sample size calculation and randomization
- Statistical Analysis Plan and formal statistical analysis/interpretation
- Program study listings, tables and figures and CDISC datasets (SDTM and ADaM)
- Define.xml and related documentation
Pharmacokinetics
- Rapid interim PK turnaround times for formulation decisions or SAD/MAD safety evaluation
- PK parameter estimation using Phoenix WinNonlin and interpretation
- Modeling and simulation using GastroPlus, including development of IVIVCs
Medical writing
- Protocol writing
- Clinical study report according to FDA guidance for industry and related submissions using eCTD specification
Standardizing study data with CDISC
When you need compliant datasets, enlist experts that understand CDISC’s impact on early phase studies and its importance to your future regulatory submission. As a CDISC Gold Member, we have built CDISC into all standard data management and statistical procedures for over 250 early phase studies. Our experts:
- Develop dataset specifications and an aCRF with reference to SDTM and ADaM implementation guides
- Program SDTM and ADaM datasets according to specifications, including verification, quality control and validation
- Provide metadata files and blankcrf.pdf
- Include all clinical, pharmacokinetic and scintigraphic data
- We also offer full define.xml package including define.pdf, trial design datasets, subject-level datasets, traceability documentation and a data reviewer’s guide
Statistics, Pharmacokinetics and Scintigraphy
Our statistical, pharmacokinetic and scintigraphic experts understand clinical pharmacology studies and their specialized challenges. Optimize your study objectives, design and subject numbers, and maximize your use of study data:
- Access input into clinical protocols and designs and ensure all output complies with the ICH, CHMP and FDA
- Provide data analysis and interpretation, such as interim assessments to assist you with real-time decision making
- Leverage expert review and interpretation of scintigraphic data, including qualitative and quantitative analysis of drug product performance and pharmacodynamic effects during your study
Resources
Lean more about Data Sciences at Quotient
-
Scientific PostersA pharmacokinetics and lung deposition study in healthy volunteersThe results of this study demonstrate that CMS delivered as ColistAir has a comparable safety profile to the comparator products and is well tolerated in healthy volunteers.
-
Scientific PostersApplication Of Non Standard Approaches To Investigations Of Human Mass Balance And Metabolite CharacterisationConventional human metabolism studies are well understood study designs which help drug companies generate data to support drug development and registration. Variations from conventional study designs can be required as a result of the specific characteristics of individual drugs or the need for particular data to support drug registration. This poster describes scenarios where alternative study designs and approaches have been required.
-
Scientific PostersAn Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675The aim of the phase 1, single-center, randomized, active-controlled study in healthy volunteers reported in this paper was to investigate the pharmacodynamic effects and safety of different dosing regimens of RDX7675 in humans.
-
Scientific PostersA rapid formulation development and clinical testing program to evaluate the pharmacokinetics of a novel enabled formulation of abiraterone acetate - AAPS 2016Following initial dosing, the Translational Pharmaceutics platform also allows GMP drug products to be made in real-time in response to interim analysis of clinical data, typically on a 7-14 day cycle.